The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer death worldwide. HCC can be cured by radical therapies if early diagnosis is done while the tumor has remained of small size. Unfortunately, diagnosis is commonly late when the tumor has grown and spread. Thus, palliative approaches are usually applied such as transarterial intrahepatic chemoembolization and sorafenib, an anti-angiogenic agent and MAP kinase inhibitor. This latter is the only targeted therapy that has shown significant, although moderate, efficiency in some individuals with advanced HCC. This highlights the need to develop other targeted therapies, and to this goal, to identify more and more pathways as potential targets. The Wnt pathway is a key component of a physiological process involved in embryonic development and tissue homeostasis. Activation of this pathway occurs when a Wnt ligand binds to a Frizzled (FZD) receptor at the cell membrane. Two different Wnt signaling cascades have been identified, called non-canonical and canonical pathways, the latter involving the β-catenin protein. Deregulation of the Wnt pathway is an early event in hepatocarcinogenesis and has been associated with an aggressive HCC phenotype, since it is implicated both in cell survival, proliferation, migration and invasion. Thus, component proteins identified in this pathway are potential candidates of pharmacological intervention. This review focuses on the characteristics and functions of the molecular targets of the Wnt signaling cascade and how they may be manipulated to achieve anti-tumor effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B. M., Delius, H., Hoppe, D., Stannek, P., Walter, C., et al. (2002) · Nature · doi:10.1038/nature756 · Cited by 1,038
β-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628 · cited 1×
“Ser37 and Ser33 phosphorylations provide a binding site for the E3 ubiquitin ligase b-TRCP (b-transducin repeat containing protein), leading to b-catenin ubiquitination in a b-TRCP/ Skp1/cullin F-box complex (SCF) dependent manner followed by proteasomal degradation [30,31].”
BackgroundGurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“therapeutic agents as well [106].”
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485
Wise, a context-dependent activator and inhibitor of Wnt signalling
Itasaki, N., Jones, C. M., Mercurio, S., Rowe, A., Domingos, P. M., Smith, J. C., & Krumlauf, R. (2003) · Development · doi:10.1242/dev.00674 · Cited by 321
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
Cancer and aging: a model for the cancer promoting effects of the aging stroma
Krtolica, A., & Campisi, J. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00053-5 · Cited by 295
Cited by
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology
Russell, J. O., & Monga, S. P. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-044010 · Cited by 471
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou, F., Shang, W., Yu, X., & Tian, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21455 · Cited by 397
WNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 351
Metadata
- Authors
- Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 59
- Issue
- 5
- Pages
- 1107-1117
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2045459429
- Cited by
- 294
- References
- 14
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs. https://app.cochat.ai/papers/10.1016/j.jhep.2013.07.001
- The paper
- Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013). Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2013.07.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.